Ocuphire Pharma Investor Day Presentation Deck
RM
68
●
●
●
Perspective from Practice Administrators on Reversing Dilations
Leading Practice Administrators Confirm the 'Market Need,' and Value to Patient
Anterior Segment Practice in Southeast
"We've explored and offered several options over the years to reverse
mydriasis - both as a tool to elevate the patient experience and to reduce
liability when a patient with poor accommodation walks out of my practice.
We've used pharmacologic agents to reverse the effects of dilation in the past,
but those products had significant limitations, and I would welcome a new
option indicated for RM in my practice." - Certified Ophthalmic Executive and
CEO
Multi-Specialty Practice, Midwest
"We call our patients guests so anything to enhance their experience is valuable for
our practice. Pupil dilation is a perceived inconvenience - especially for the working-
age population. They grab up our evening appointments typically, so they don't have
to go back to work while dilated. Having an option to reverse dilation is something we
and our guests would enjoy." - Certified Ophthalmic Executive and CEO
Leading Academic Eye Center
"Patients have anxiety over dilation and if we could reduce that fear, help them
regain accommodation faster, I would like to consider that option across all
specialties." - Head of Operations, Certified
Practice Administrator Interviews Conducted by Ocuphire
Willingness to Implement:
We would be comfortable
passing this cost to the
patient as a premium to
resume visual function
faster.
N
Patients would be willing
to pay for this benefit.
Ocuphire
PHARMAView entire presentation